Chief, Disease Modeling and Transmission Section
Chief, Laboratory of Virology
Chief Scientist of the RML BSL4 Laboratories
Education:
Ph.D., 1988, University of Marburg, Germany
M.D., 1987, University of Marburg, Germany
Biography
Heinz Feldmann graduated from Medical School in 1987 (MD) and received his Ph.D. in 1988 both from the University of Marburg, Germany. His postdoctoral research was conducted in the field of virology (filoviruses and hantaviruses) at the Institute of Virology in Marburg and the Centers for Disease Control and Prevention in Atlanta, USA (‘National Research Council’ fellowship). His academic career continued with positions as Assistant and Associate Professor at the Institute of Virology in Marburg. During this time, he was trained in infectious diseases and epidemiology. From 1999-2008, Heinz Feldmann held the position of Chief, Special Pathogens Program of the National Microbiology Laboratory, Public Health Agency of Canada. Since 2008, he is the Chief, Laboratory of Virology, and the Chief Scientist of the BSL4 Laboratories at the Rocky Mountain Laboratories, NIAID, NIH. Heinz Feldmann is a laboratory expert on high containment pathogens and serves as a consultant on emerging viruses for the World Health Organization. He has field experience and expertise in outbreak management. His research interest is in the pathogenesis and transmission of emerging viral pathogens, and the development of countermeasures against those pathogens. Heinz Feldmann was awarded with several honors including the ‘Löffler-Frosch Award’ from the German Society for Virology, the ‘Dalrymple/Young Award’ from the American Committee on Arthropod-Borne Viruses, and several Research Merit Awards from the Public Health Agency of Canada, the NIAID and the NIH. He is an elected member of the German Academy of Science (Leopoldina), the US National Academy of Medicine and the American Academy of Microbiology. His major scientific achievements of public health significance are the design and foundation of on-site laboratory support, the establishment of diverse animal disease models, and the development of treatments (e.g. antibodies, polymerase inhibitors) and vaccines (e.g. VSV-EBOV, Ervebo) for emerging/re-emerging viral pathogens.